Human papillomaviruses (HPVs) are the causative factor for 490% of cervical cancers and 25% of head and neck cancers. The incidence of HPV positive ( þ ) head and neck squamous cell carcinomas has greatly increased in the last 30 years. E6 and E7 are the two key viral oncoproteins that induce and propagate cellular transformation. An immune response generated during cisplatin/ radiation therapy improves tumor clearance of HPV( þ ) cancers. Augmenting this induced response during therapy with an adenoviral HPV16 E6/E7 vaccine improves long-term survival in pre-clinical models. Here, we describe the generation of an HPV16 E6/E7 construct, which contains mutations that render E6/E7 non-oncogenic, while preserving antigenicity. These mutations do not allow E6/E7 to degrade p53, pRb, PTPN13, or activate telomerase. Non-oncogenic E6/E7 (E6 D /E7 D ) expressed as a stable integrant, or in the [E1-, E2b-] adenovirus, lacks the ability to transform human cells while retaining the ability to induce an HPV-specific immune response. Moreover, E6 D /E7 D plus chemotherapy/radiation statistically enhances clearance of established HPV( þ ) cancer in vivo.
INTRODUCTION
The majority of individuals diagnosed with oropharyngeal (base of tongue, tonsil) head and neck squamous cell carcinoma (HNSCCs) are infected with high risk human papillomaviruses (HPVs). Greater than 90% of these individuals with HPV( þ ) cancers are infected with HPV type 16 . Although the incidence of HPV negative ( À ) HNSCC is declining, the incidence of HPV( þ ) HNSCC is on the rise and has tripled in recent years.
1,2 HPV( þ ) patients often do not have a significant tobacco history and present with a more advanced disease stage compared with their HPV( À ) counterparts, suggesting HPV( þ ) HNSCC is a distinct virally mediated disease. 3, 4 The development of new treatments, which specifically target HPV( þ ) disease, and advancements in existing therapies that improve survival are imperative for this cancer type.
Current treatment of HNSCC with non-specific chemotherapy and radiation, which results in significant morbidity, could be improved with addition of immunotherapy. Known viral oncogenes are attractive candidates as targets for immunotherapy. The HPV viral oncoproteins, E6 and E7, are predominantly responsible for transformation in HPV( þ ) HNSSCs. Like many viral oncoproteins, E6/E7 are expressed early in the course of infection and have multifunctional roles. E6 promotes degradation of p53, indirectly activates telomerase, and disrupts the function of the cellular phosphatase tumor suppressor PTPN13. [5] [6] [7] [8] E7 inactivates pRb and activates Mi2b. 5, 9 Together, these oncogenic alterations drive rapid cellular proliferation, suppress or downregulate key tumor suppressor proteins, and lead to cellular immortality. In addition, E6/E7 expression is vital for malignancy and is required to maintain a malignant transformed phenotype. 10, 11 Currently, no HPV vaccine is effective at treating established disease, despite their success with preventing infection. 12 Vaccine prevention of high risk HPV infection will likely fail as HPV infection of the tonsil epithelia occurs early in life, before when immunization is currently administered. 13 Current HPV16 vaccines utilize viral coat proteins or virus-like particles with HPV16 late gene products; however, many HPV( þ ) HNSCC express early (E6/ E7) rather than late viral genes such as the viral coat proteins. Thus, vaccination with viral coat proteins might be ineffective for treating established cancer 14 and an immune-based therapeutic vaccine to the viral oncogenes, E6/E7, may prove more effective.
Our pre-clinical model of HPV( þ ) HNSCC supports the effectiveness of an E6/E7 immunotherapeutic vaccine. 15, 16 The immune response that develops in animals bearing HPV( þ ) tumors is required to achieve tumor clearance in conjunction with cisplatin and radiation treatment, a regimen most often clinically used. 16 Boosting the immune response with recombinant adenovirus expressing HPV E6/E7 improves long-term cures by as much as 30% over standard cisplatin/radiation alone. 16 Though encouraging, two obstacles remain before bringing this therapy to trial in humans.
Pre-existing adenoviral immunity severely limits the usefulness of an adenovirus-based vaccine strategy. To negate this problem, we utilized an E1-, E2b-deleted adenovirus (Ad5 [E1-, E2b-]) that induces effective immune stimulation despite the generation of vector-induced Ad5 immunity. 17 The second obstacle is the expression of active viral oncogenes presents potential risks despite delivery via a non-replicating recombinant adenovirus. Potential transgene integration of the HPV oncogene(s) into the host genome may initiate cellular proliferation, transformation and immortalization. To address this risk, we inactivated the E6/E7 coding regions responsible for oncogenic transformation. E6 and E7 have been well studied and their oncogenic coding sites previously described. 10, 18 In this report, we describe the generation of a full-length E6/E7 vaccine in which the known oncogenic transforming regions are inactivated. The E6 D /E7 D cassette does not retain cellular oncogenic functions, yet retains antigenicity allowing vaccine treatment of established HPV-related cancer in vivo.
MATERIALS AND METHODS

Mutagenisis of HPV16 E6/E7 oncogenes
In vitro site-directed mutagenesis of HPV E6/E7 oncogenes was performed as per manufacturer directions (Aligent Technologies, Santa Clara, CA). Mutated regions: leucine to glycine mutation at position 50 of E6 was generated; this region encompasses the p53 binding and telomerase activation site (L50G forward primer: 5 0 -GACTATTTTGCTTTTCGGGATGGAT-G-3 0 ; L50G reverse primer: 5 0 -CCCATCTCTATATACTATGCATCCATC-3 0 ). Second, the C-terminal PDZ-binding domain of E6 (glutamic acid, threonine, glutamine and leucine) at residues 146-151 was mutated to four alanines (PDZ forward primer: 5 0 -GAACTCGTAGAGCAGCCGCG-GCGTA-3 0 ; PDZ reverse primer: 5 0 -GTGTATCTCCATGCATGATTACGCCG-3 0 ). Third, three single-point mutations in HPV16 E7 at the Rb binding sites were generated as follows: histidine to proline at residue 2 (H2P forward primer; 5 0 -CAGCCGCGGCGTAATCATGCCT-GGA-3 0 ; H2P reverse primer: 
Viral construction
) and wild-type E6/E7 (Ad5 [E1-, E2b-]-wt-E6/E7) were constructed and produced as previously described. 17, 19 Briefly, the transgenes were sub-cloned into the E1 region of the Ad5 [E1-, E2b-] vector using a homologous recombinationbased approach. The replication-deficient virus was propagated in the E.C7 packaging cell line, CsCl 2 purified and titered as previously described. 17 Viral infectious titer was determined as PFU (plaque forming units) on an E.C7 cell monolayer. The viral particle (VP) concentration was determined by SDS disruption and spectrophotometry at 260 and 280 nm. 17, 20 The ratio of VP to PFU was 36.7/1 VP/PFU. The E6
D
/E7
D insert as well as the wt-E6/E7 were then cut and ligated into the retroviral vector pLXSN using EcoRI and BamHI restriction sites. Retrovirus particles were generated in the Phoenix A cell line according to manufacturer's recommendations (American Type Culture Collection, Manassas, VA) with polybrene (Sigma, St Louis, MO) added to a final concentration of 8 mg ml À 1 .
Cells A549 (human adenocarcinoma alveolar basal epithelium cell line) cells were grown in Dulbecco's modified Eagle medium (Thermo Fisher, Logan, UT) supplemented with 10% fetal bovine serum (Thermo Fisher). Primary human tonsil epithelial (HTE) cells were isolated from surgical tonsillectomy of consented patients under institutional IRB approval as previously described. 21 HTE cells were maintained in Keratinocyte SFM media (KSFM; Invitrogen, Carlsbad, CA). Mouse tonsil epithelial cells expressing HPV16 E6, E7, Ras and luciferace (mEERL) have been previously described 21 and were maintained in DMEM supplemented with 22.5% Hams F-12 medium, 10% heat inactivated FCS, 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin, 0.5 mg ml À 1 hydrocortisone, 0.0084 mg ml À 1 cholera toxin, 5 mg ml À 1 transferrin, 5 mg ml À 1 insulin, 0.00136 mg ml 
D cell lines were measured as described previously. 22, 23 Cells were grown to 80% confluency, harvested by trypsinization, counted and re-suspended to 400 000 cells per ml. Cells were lysed for 30 min on ice in CHAPS lysis buffer (0.5% Chaps; 10 mM Tris, pH 7.5; 1 mM MgCl 2 ; 1 mM EGTA, 5 mM 2-ME; 10% glycerol; 0.1 mM 4-(2-amino-ethyl)benzene-sulfonyl fluoride hydrochloride (AEBSF). Membranes were pelleted by centrifugation (10 000 
Adenoviral infection of cell lines HTE cells grown to 80% confluency were infected with
D , or Ad GFP at an MOI of 100 for 24 h. DNA was collected at passages 1, 2, 3, 4 and 5 post-infection. Cells were trypsinized, rinsed and re-suspended in 1 Â phosphate buffered saline. DNA extraction was performed using a standard animal tissue spin-column protocol from DNeasy DNA Blood and Tissue Kit (Qiagen, Valencia, CA).
Quantitative real-time PCR was performed to assay for HPV16 copy number. Briefly, HPV 16 primer set 520 5 0 -TTGCAGATCATCAAGAACACG TAGA-3 0 and 671 5 0 -CTTGTCCAGCTGGACCATCTATTT-3 0 along with an 18S primer set (Applied Biosystems) were used. The amplification reaction contained SyberGreen Universal Master Mix (Applied Biosystems) 250 nM HPV 16 primers or 100 nM 18S primers and 25 ng template. Cycling conditions were 95 1C for 10 min with 40 cycles at 95 1C for 15 s and 60 1C for 60 s using the Stratagene Mx3000P thermocycler.
Western blot analysis
The following stable cell lines A549 wt-E6/E7, A549 E6 D /E7 D , and parental A549 cells were grown to 80-90% confluency, rinsed with PBS and harvested with lysis solution (50 mM Tris HCl pH 7.5; 150 mM NaCl; 5 mM EDTA; 2 mM Na 3 VO 4 ; 100 mM NaF; 10 mM NaPPi; 10% glycerol; 1% Triton; 1 Â halt protease inhibitors; 17.4 mg ml À 1 PMSF). Membranes were pelleted by centrifugation (10 000 r.p.m. at 4 1C) and soluble proteins collected. Total protein was quantified using the BCA protein assay kit as per the manufacturer's directions (Pierce, Logan, UT) and equal total protein was analyzed by western blot. Briefly, proteins were separated by SDS-PAGE, transferred to PVDF-membranes (Immobilon-P), blocked with either 5% bovine serum albumin (MP Biomedicals, Solon, OH) or non-fat dry milk and visualized by chemiluminescence on film or via UVP bioimaging system (Upland, CA). Membranes were incubated with the following antibodies: FAP-1 (1:500, Santa Cruz, Santa Cruz, CA), p53 (1:500, Calbiochem, Darmstadt, Germany), pRb (1:250, BD Biosciences, Sparks, MD) and GAPDH (1:5 000, Ambion, Carlsbad, CA).
Immunization of mice with Ad5 [E1-, E2b-]-E6
D /E7 D for immune assays 
/E7
D . Two weeks after the last injection/immunization, all mice were killed and spleens harvested. Splenocytes from each mouse were isolated for enzyme-linked immunospot (ELISpot) testing as described below. Serum from each mouse was collected and stored at À 20 1C until testing.
Preparation of mEERL cell lysates for ELISpot HPV( þ ) (mEERL) cells were grown in a T125 flask until confluent, after which cells were aseptically scraped off the plastic surface, washed three times with sterile PBS, and re-suspended in 1 ml of sterile PBS. Cells were lysed by freeze-thawing three times and cellular debris removed by centrifugation. Soluble protein was brought to a final volume of 2 ml with sterile PBS. The presence of HPV-E7 in the lysate was confirmed by western blot analysis performed as described. 24 ELISpot assays HPV16 E6 and E7-specific IFN-g and IL-2 production from splenocytes isolated from individual mice following immunizations was detected by ELISpot as previously described. 19 Briefly, cells were stimulated with HPV16 E6 and E7 peptides (15-mer peptide complete sets for each; JPT Peptide Technologies, Berlin, Germany). Peripheral blood mononuclear cells were used at a concentration of 2 Â 10 5 cells per well and reported as the number of spot forming cells (SFCs) per 10 6 cells per well. All E6 peptides were combined and tested as a single pool. Similarly, all E7 peptides were combined and tested as a single pool. Each peptide pool was tested in duplicate. To test for specificity, splenocytes were also exposed to an HIVgag peptide pool and a cytomegalovirus (CMV) peptide pool. Peptides were utilized at 0.1 mg of each peptide per well. To test for reactivity to mEERL cell lysate, 25 ml of lysate was added to test wells in duplicate. In all ELISpot assays, cells stimulated with concanavalin A at a concentration of 1 mg per well served as positive controls. Colored SFC were counted using an Immunospot ELISpot plate reader (Cellular Technology, Shaker Heights, OH) and responses considered positive if, (1) 50 SFC were detected/10 6 cells after subtraction of the negative control or (2) SFC were at least twofold greater than those in the negative control wells and significantly elevated.
ELISpot: mouse granzyme B assay ELISpot mouse Granzyme B kit (R&D Bio Systems, Minneapolis, MN) methods were followed as per manufacturer's instructions with the following changes. Briefly, splenocytes were incubated with mEERL for 4 h to stimulate Granzyme B production. In all, 5 Â 10 5 splenocytes were added to wells of ELISpot plate and placed at 37 1C with CO 2 for 2 h. D intranasally. Cisplatin (CalBiochem) 20 mg m À 2 administered i.p. and concurrent radiation (8 Gy Xray (Rad Source RS2000 irradiator, Brentwood, TN)) was administered on days 13, 20, 27 days post-tumor implantation. Tumor growth was monitored weekly using caliper measurements and tumor volume calculated using the following formula, volume ¼ (width 2 )(depth). Mice were killed when tumors reached 1.5 cm in any dimension, the animal became emaciated, or demonstrated functional leg impairment. Long-term survival was followed for 470 days.
Statistical analysis
Statistically significant differences in the mean immune responses between groups of animals were determined by Student's t-test using GraphPad Prism (GraphPad Software, La Jolla, CA). Statistically significant differences for mouse in vivo survival analysis were determined by Kaplan-Meier log-rank survival using SigmaPlot 11 (Systat Software, San Jose, CA).
RESULTS
E6/E7 mutations
To decrease the risk associated with adenoviral delivery of HPV E6/ E7 we mutated six known oncogenic regions within E6 and E7 10, 25 ( Figure 1a) . The introduced mutations destroy the ability of E6 to mediate degradation of p53, activate telomerase and bind at the PDZ motif. 6, 7 The E6 PDZ binding motif participates in transformation by inactivating the tumor suppressor protein PTPN13 and other proteins with PDZ domain interactions. 8, 26, 27 Mutations introduced in E7 prevent its ability to bind/inactivate pRb and other pocket proteins, and to associate with Mi2b that enhances cellular growth. 9 Figure 1b shows an amino acid (Figure 2b ) suggesting that the changes evident by western blot were a consequence of altered oncogene function rather than expression and confirm the biochemical loss-of-function in the E6 D /E7 D construct. Telomerase activity was also examined in these clones. As predicted, the E6 D / E7 D and vector control did not show telomerase activation, whereas the wt-E6/E7 enhanced it (Figure 2c) . Previous studies have shown that HPV wt-E6/E7 induces morphological mesenchymal type changes. 28 Therefore, the morphological characteristics of clones were also examined. Figure 2d shows 30, 31 However, the effect(s) of HPV E6/E7 in the context of this vector have not been previously examined. Wt-E6/E7 was able to induce loss of p53, whereas E6 D / E7 D was able to rescue p53 levels compared with control ( Figure 3b) . However, neither wt-E6/E7 nor E6 D /E7 D were able to immortalize primary tonsil epithelial cells after infection 
/E7
D grow in tight colonies, whereas A549 wt-E6E7 exhibit spindle/mesenchymal morphology and do not form tight colonies. (Figure 3c ). To determine if this was due to viral loss with replication, we examined the persistence of viral DNA in association with cell growth. Q-PCR demonstrated that as cells replicated, viral DNA was lost at a similar rate with all inserts, suggesting the viral genes did not integrate into the host cell DNA (Figure 3d) . Therefore, HPV genes from the Ad5 [E1-, E2b-] vector do not persist as cellular division continues. Moreover, the transient expression of wt-E6/E7 in this setting was not sufficient to transform primary cells. The specificity of the CMI responses was demonstrated by a lack of reactivity when splenocytes were exposed to the irrelevant antigens HIV-gag or CMV. Functionally active splenocytes in all groups was verified by positive responses to concanavalin A. Granzyme B assay was also examined because it reflects immune related tumor cell toxicity assays. 32 Splenocytes from mice vaccinated with both E6/E7 vaccines showed significant increase in cell-mediated tumor cell toxicity compared with non vaccinated mice splenocytes (Figure 4c ). These results indicate that the non-oncogenic E6 D /E7 D is immunogenic and induces an HPV-specific E6/E7 CMI response.
E6
D /E7 D immunotherapy increases survival during concurrent chemotherapy/radiation We have previously shown that mice intranasally vaccinated with and Adenovirus expressing wild-type E6/E7 improved long-term survival in mice receiving standard cisplatin/radiation. 16 Although the in vitro tests suggested that mice receiving the Ad5 [E1-, E2b-]-E6 D /E7 D vector had a similar anti-HPV immune response, we wanted to test if it would enhance clearance of HPV þ tumors similar to the wild-type oncogenes. To test the efficacy of the nononcogenic E6 D /E7 D we established HPV( þ ) tumors in wild-type mice identically as previously shown. 16 Once tumors had established for 1 week Ad5 [E1-, E2b-]-E6 D
/E7
D or Ad5 [E1-, E2b-]-null was delivered intranasally weekly for 3 weeks. Mice receiving only cisplatin/xrt þ Ad5 [E1-, E2b-]-null (vector control) had similar and long-term clearance as we had previously reported. 16 However, mice receiving Ad5 [E1-, E2b-]-E6 D /E7 D had significantly improved long-term survival ( Figure 5 ) mimicking the response we had seen in the past studies when we had delivered wildtype E6/E7. 16 These data show that in immune competent mice vaccination with Ad5 [E1-, E2b-]-E6 D /E7 D enhances immune related clearance in vivo during standard therapy for HPVrelated cancer. 
DISCUSSION
We describe the generation of a novel HPV16 E6/E7 construct containing a combination of modifications that render these viral oncogenes non-oncogenic while retaining the antigenicity necessary to produce an immunotherapeutic vaccine against HPV( þ ) tumors. We demonstrated biochemically that these mutations lack the capacity to degrade p53, pRb and PTPN13. D /E7 D antigens are 'non-self' with less potential to induce autoimmunity than with other tumor-associated antigens.
The delivery of the modified viral antigens is also of critical importance to the success of the vaccine. We chose an adenoviral vector as it has been repeatedly used in humans to induce robust CMI responses. Adenovirus can be mass-produced, is stable, and has an extensive safety profile. The new Ad5 [E1-, E2b-] vector has been successfully studied in other pre-clinical animal models of cancer. 31, 33 Additionally, infectious disease models utilizing the Ad5 [E1-, E2b-] vector suggest efficacy in NHP (non-human primates). 34 The CMI responses induced by Ad5 [E1-, E2b-] in Ad5 naïve and Ad5 immune NHP increased over a course of multiple immunizations and the response profiles observed in Ad5 naïve and Ad5 immune NHP were similar. These previous findings suggest that the new Ad5 [E1-, E2b-]-based vaccine could be used for homologous vaccination regimes to induce robust CMI responses in the presence of Ad5 vector immunity.
Several pre-clinical studies suggest a therapeutic immune-based vaccine strategy using E6 and/or E7 may be of value in the treatment of established disease. [35] [36] [37] However, these published studies include vaccines utilizing specific regions of either E6 and/or E7. [38] [39] [40] By expressing slightly varied non-oncogenic full-length forms of both E6 and E7, our strategy has the advantage of maintaining native antigenic processing and thus theoretically increasing the chance of an immune response in vivo. Given the heterogeneity of immune response in humans, which is much less predictable than inbred strains of mice, expression of full-length proteins allows for antigen processing and development of a CMI response that may produce a broad and effective anti-tumor response.
HPV16 is the most common cause of cervical, oropharynx and anal cancers and common therapies (cisplatin and radiation) are used for treatment in the advanced stages of these cancers. Even though we examined a pre-clinical model of HPV( þ ) oropharynx cancer, it is likely that similar principles of therapy and vaccination can be used for other HPV( 
